The United States Food and Drug Administration (FDA) has approved the use of CAR-T cells targeting the cluster of differentiation 19 (CD19) (54–56) and the B-cell maturation antigen (BCMA) (57, 58) for the treatment of hematological malignancies. This evidence concerns the gene TNFRSF17 and hematologic disorder.